Real-World Study Confirms GLP-1 Drugs Significantly Reduce BMI, Blood Sugar, and HbA1c in Type 2 Diabetes | Research

The takeaway

In 1,000 patients with type 2 diabetes, GLP-1 receptor agonists reduced BMI by an additional 1.02 kg/m², fasting glucose by 21.3 mg/dL, and HbA1c by 0.58% over 24 months compared to other second-line diabetes drugs.

-1.02 kg/m² BMI advantage
GLP-1RAs outperformed other second-line diabetes drugs for weight reduction in 1,000 real-world patients over 24 months

What the researchers found

GLP-1RAs reduced BMI by 1.02 kg/m² (95% CI: -1.46 to -0.58), FPG by 21.34 mg/dL (95% CI: -29.53 to -13.15), and HbA1c by 0.58% (95% CI: -0.77 to -0.38) more than other second-line treatments over 24 months.

Why it matters

Clinical trials show GLP-1 drugs work, but real-world confirmation is essential because trial patients are carefully selected. This study confirms that the benefits translate to everyday clinical practice and quantifies the advantage over other second-line options.

The numbers in context

Study period: 2010-2023. Used linear mixed-effect regression with heterogeneous augmented inverse probability weighting for robust comparisons.

How the study worked

Retrospective cohort study using difference-in-differences analysis with heterogeneous augmented inverse probability weighting. 1,000 patients with T2DM (220 GLP-1RA, 880 non-GLP-1RA) from 2010-2023.

Who was studied

Adults with type 2 diabetes receiving GLP-1RA or other second-line treatments (2010-2023)

What this study cannot tell us

Retrospective design with potential for unmeasured confounders. Unequal group sizes (220 vs 880). Specific GLP-1RA agents were not separately analyzed. 24-month follow-up may not capture long-term outcomes. Single healthcare setting.

How to read the evidence

Moderate evidence from a well-designed real-world retrospective study using robust statistical methods. Consistent with clinical trial data.

When this study was published

Published in 2024, analyzing data from 2010-2023.

The bigger picture

As GLP-1 drugs become more widely prescribed and more formulations become available, real-world evidence confirming their superiority over older second-line options strengthens the case for using them earlier in the diabetes treatment pathway.

Questions still open

Which specific GLP-1RA shows the best real-world outcomes in this population?
Do the benefits increase or plateau beyond 24 months of treatment?
How do the results compare when stratified by initial BMI or diabetes duration?

Common questions

How much more effective are GLP-1 drugs compared to other diabetes medications?

Over 24 months, GLP-1 drugs reduced BMI by about 1 kg/m² more, fasting blood sugar by about 21 mg/dL more, and HbA1c by about 0.58% more than other second-line diabetes treatments. These differences are clinically meaningful.

Should all type 2 diabetes patients switch to GLP-1 drugs?

This study supports GLP-1 drugs as the preferred second-line option for patients who are overweight and not well-controlled on metformin. However, treatment decisions should consider individual factors like cost, insurance coverage, side effect tolerance, and patient preference.

Read the original research

Effectiveness of glucagon-like peptide-1 receptor agonists for reduction of body mass index and blood glucose control in patients with type 2 diabetes mellitus and obesity: A retrospective cohort study and difference-in-difference analysis.

BMJ open, 14(11), e086424

View on PubMed ↗Publisher’s paper ↗

Citation

Siriyotha, Sukanya; Anothaisintawee, Thunyarat; Looareesuwan, Panu; Nimitphong, Hataikarn; McKay, Gareth J; Attia, John; Thakkinstian, Ammarin. (2024). Effectiveness of glucagon-like peptide-1 receptor agonists for reduction of body mass index and blood glucose control in patients with type 2 diabetes mellitus and obesity: A retrospective cohort study and difference-in-difference analysis.. BMJ open, 14(11), e086424. https://doi.org/10.1136/bmjopen-2024-086424